Invention Grant
- Patent Title: Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
-
Application No.: US15688009Application Date: 2017-08-28
-
Publication No.: US10744154B2Publication Date: 2020-08-18
- Inventor: David Platt , Eliezer Zomer , Anatole Klyosov
- Applicant: Galectin Therapeutics, Inc.
- Applicant Address: US GA Norcross
- Assignee: Galectin Therapeutics, Inc.
- Current Assignee: Galectin Therapeutics, Inc.
- Current Assignee Address: US GA Norcross
- Agency: Greenberg Traurig, LLP
- Agent Barry Schindler; Natalie Salem
- Main IPC: A61P13/12
- IPC: A61P13/12 ; A61K31/715 ; C08B37/00 ; A61K31/732 ; A61K39/395 ; A61K45/06

Abstract:
Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.
Public/Granted literature
- US20180042958A1 GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES Public/Granted day:2018-02-15
Information query